Rituximab Plus Lenalidomide or Rituximab Monotherapy for Untreated Patients With Follicular Lymphoma in Need of Therapy. A Randomized, Open-Label, Multicenter Phase II Trial.

Trial Profile

Rituximab Plus Lenalidomide or Rituximab Monotherapy for Untreated Patients With Follicular Lymphoma in Need of Therapy. A Randomized, Open-Label, Multicenter Phase II Trial.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 10 May 2017

At a glance

  • Drugs Lenalidomide (Primary) ; Rituximab
  • Indications Follicular lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Dec 2016 Results of first analysis of secondary endpoints presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 06 Dec 2016 Results (n=13) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 14 Apr 2016 Planned End Date changed from 1 Dec 2015 to 1 Mar 2023.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top